436 related articles for article (PubMed ID: 31109210)
1. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.
Kuo YC; Rajesh R
Expert Rev Neurother; 2019 Jul; 19(7):623-652. PubMed ID: 31109210
[No Abstract] [Full Text] [Related]
2. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
Khan A; Corbett A; Ballard C
Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
[TBL] [Abstract][Full Text] [Related]
5. Status and future directions of clinical trials in Alzheimer's disease.
Plascencia-Villa G; Perry G
Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
[TBL] [Abstract][Full Text] [Related]
6. Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.
Ryan P; Patel B; Makwana V; Jadhav HR; Kiefel M; Davey A; Reekie TA; Rudrawar S; Kassiou M
ACS Chem Neurosci; 2018 Jul; 9(7):1530-1551. PubMed ID: 29782794
[TBL] [Abstract][Full Text] [Related]
7. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
8. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
Cho JE; Kim JR
Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
[TBL] [Abstract][Full Text] [Related]
9. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
Xie Y; Tan Y; Zheng Y; Du X; Liu Q
J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
[TBL] [Abstract][Full Text] [Related]
10. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
11. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
[TBL] [Abstract][Full Text] [Related]
12. βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease.
Audrain M; Souchet B; Alves S; Fol R; Viode A; Haddjeri A; Tada S; Orefice NS; Joséphine C; Bemelmans AP; Delzescaux T; Déglon N; Hantraye P; Akwa Y; Becher F; Billard JM; Potier B; Dutar P; Cartier N; Braudeau J
Cereb Cortex; 2018 Nov; 28(11):3976-3993. PubMed ID: 29048465
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
14. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
Savelieff MG; Lee S; Liu Y; Lim MH
ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
[TBL] [Abstract][Full Text] [Related]
15. Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.
Gu JL; Liu F
Curr Med Sci; 2020 Dec; 40(6):1009-1021. PubMed ID: 33428128
[TBL] [Abstract][Full Text] [Related]
16. Notopterygium incisum extract (NRE) rescues cognitive deficits in APP/PS1 Alzhneimer's disease mice by attenuating amyloid-beta, tau, and neuroinflammation pathology.
Jiang XW; Liu WW; Wu YT; Wu Q; Lu HY; Xu ZH; Gao HY; Zhao QC
J Ethnopharmacol; 2020 Mar; 249():112433. PubMed ID: 31783135
[TBL] [Abstract][Full Text] [Related]
17. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
Golde TE; Petrucelli L; Lewis J
Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
19. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
Barage SH; Sonawane KD
Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
[TBL] [Abstract][Full Text] [Related]
20. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
Huber CM; Yee C; May T; Dhanala A; Mitchell CS
J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
